MX342181B - Formulaciones que comprenden polietilenglicol. - Google Patents
Formulaciones que comprenden polietilenglicol.Info
- Publication number
- MX342181B MX342181B MX2013004972A MX2013004972A MX342181B MX 342181 B MX342181 B MX 342181B MX 2013004972 A MX2013004972 A MX 2013004972A MX 2013004972 A MX2013004972 A MX 2013004972A MX 342181 B MX342181 B MX 342181B
- Authority
- MX
- Mexico
- Prior art keywords
- polyethylene glycol
- solid
- formulations
- formulation
- suckable
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000002202 Polyethylene glycol Substances 0.000 title abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 title abstract 2
- 239000007787 solid Substances 0.000 abstract 4
- 206010010774 Constipation Diseases 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1018647.6A GB201018647D0 (en) | 2010-11-04 | 2010-11-04 | Formulations |
| US41210910P | 2010-11-10 | 2010-11-10 | |
| GBGB1104049.0A GB201104049D0 (en) | 2011-03-09 | 2011-03-09 | Formulations |
| GBGB1107626.2A GB201107626D0 (en) | 2011-05-06 | 2011-05-06 | Formulations |
| PCT/GB2011/001560 WO2012059724A1 (en) | 2010-11-04 | 2011-11-04 | Formulations comprising polyethylene glycol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013004972A MX2013004972A (es) | 2013-08-27 |
| MX342181B true MX342181B (es) | 2016-09-20 |
Family
ID=44999794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013004972A MX342181B (es) | 2010-11-04 | 2011-11-04 | Formulaciones que comprenden polietilenglicol. |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20130225692A1 (enExample) |
| EP (1) | EP2635264B8 (enExample) |
| JP (1) | JP5872573B2 (enExample) |
| KR (1) | KR20130101102A (enExample) |
| CN (1) | CN103384516B (enExample) |
| AR (1) | AR083769A1 (enExample) |
| AU (1) | AU2011324995B2 (enExample) |
| BE (1) | BE1019493A3 (enExample) |
| BR (1) | BR112013010884A2 (enExample) |
| CA (1) | CA2816835A1 (enExample) |
| EA (1) | EA024566B1 (enExample) |
| ES (1) | ES2405531B1 (enExample) |
| IL (1) | IL225892A0 (enExample) |
| MX (1) | MX342181B (enExample) |
| MY (1) | MY164204A (enExample) |
| NL (1) | NL2007716C2 (enExample) |
| NZ (1) | NZ611148A (enExample) |
| SG (1) | SG190018A1 (enExample) |
| TW (1) | TWI520730B (enExample) |
| WO (1) | WO2012059724A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI535461B (zh) | 2011-03-11 | 2016-06-01 | 諾金私人有限公司 | 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法 |
| WO2013119582A1 (en) * | 2012-02-06 | 2013-08-15 | University Of Utah Research Foundation | Drug release from a polymer-controlled local antibiotic delivery system using a degradable bone graft |
| KR20170098980A (ko) | 2012-09-11 | 2017-08-30 | 노어긴 비.브이. | Peg 및 아스코르베이트를 포함하는 조성물 |
| US9889235B2 (en) | 2013-02-05 | 2018-02-13 | University Of Utah Research Foundation | Implantable devices for bone or joint defects |
| EP3563838A1 (en) | 2013-03-15 | 2019-11-06 | Braintree Laboratories, Inc. | Dual use oral pharmaceutical composition tablets of suflate salts and methods of use thereof |
| JP2017514521A (ja) * | 2014-04-29 | 2017-06-08 | コロナリーコンセプツ エルエルシー | 電解質補給物をもたらすための食品、システム、方法、及びキット |
| CA2997221A1 (en) * | 2015-09-01 | 2017-03-09 | Colonaryconcepts Llc | Laxative formulations and manufacture |
| JP6680356B2 (ja) | 2016-06-15 | 2020-04-15 | 株式会社島津製作所 | 放射線撮影装置 |
| FR3056109B1 (fr) | 2016-09-21 | 2019-10-11 | Pierre Fabre Medicament | Utilisation de formulations solides de polyethylene glycol dans le traitement de la constipation |
| CN112386577B (zh) * | 2019-08-16 | 2024-01-23 | 北京天衡药物研究院有限公司 | 一种治疗便秘的组合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5710183A (en) * | 1995-07-14 | 1998-01-20 | Halow; George M. | Laxative/antidiarrheal composition comprising polyethylene glycol and fiber bulking agent |
| MXPA05009079A (es) * | 2003-02-28 | 2006-05-19 | Alk Abello As | Forma de dosificacion que tiene una matriz de sacarido. |
| GB0409104D0 (en) * | 2004-04-23 | 2004-05-26 | Norgine Europe Bv | Compressed pharmaceutical compositions |
| JP5276435B2 (ja) * | 2005-05-06 | 2013-08-28 | セイリックス ファーマシューティカルズ， インコーポレイティッド | ポリエチレングリコールの結腸の下剤組成物 |
| CO5790164A1 (es) * | 2006-08-10 | 2007-08-31 | Procaps S A | Composicion farmaceutica solida que incluye en combinacion un agente regulador de la motilidad intestinal y un agente antiflatulento |
-
2011
- 2011-11-04 NL NL2007716A patent/NL2007716C2/en active
- 2011-11-04 EP EP11785049.5A patent/EP2635264B8/en active Active
- 2011-11-04 CA CA2816835A patent/CA2816835A1/en not_active Abandoned
- 2011-11-04 TW TW100140230A patent/TWI520730B/zh not_active IP Right Cessation
- 2011-11-04 CN CN201180063942.9A patent/CN103384516B/zh not_active Expired - Fee Related
- 2011-11-04 KR KR1020137013975A patent/KR20130101102A/ko not_active Ceased
- 2011-11-04 ES ES201131774A patent/ES2405531B1/es active Active
- 2011-11-04 EA EA201300539A patent/EA024566B1/ru not_active IP Right Cessation
- 2011-11-04 SG SG2013031984A patent/SG190018A1/en unknown
- 2011-11-04 WO PCT/GB2011/001560 patent/WO2012059724A1/en not_active Ceased
- 2011-11-04 US US13/883,153 patent/US20130225692A1/en not_active Abandoned
- 2011-11-04 MY MYPI2013001599A patent/MY164204A/en unknown
- 2011-11-04 AU AU2011324995A patent/AU2011324995B2/en active Active
- 2011-11-04 BR BR112013010884A patent/BR112013010884A2/pt not_active IP Right Cessation
- 2011-11-04 MX MX2013004972A patent/MX342181B/es active IP Right Grant
- 2011-11-04 AR ARP110104128A patent/AR083769A1/es unknown
- 2011-11-04 JP JP2013537196A patent/JP5872573B2/ja active Active
- 2011-11-04 BE BE2011/0644A patent/BE1019493A3/fr active
- 2011-11-04 NZ NZ611148A patent/NZ611148A/en not_active IP Right Cessation
-
2013
- 2013-04-22 IL IL225892A patent/IL225892A0/en unknown
-
2016
- 2016-01-14 US US14/995,537 patent/US20160193245A1/en not_active Abandoned
-
2017
- 2017-06-28 US US15/635,897 patent/US20170296575A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011324995A1 (en) | 2013-05-02 |
| CA2816835A1 (en) | 2012-05-10 |
| ES2405531R1 (es) | 2013-06-07 |
| EP2635264B1 (en) | 2018-05-30 |
| CN103384516B (zh) | 2017-02-15 |
| US20160193245A1 (en) | 2016-07-07 |
| US20170296575A1 (en) | 2017-10-19 |
| WO2012059724A8 (en) | 2013-06-06 |
| EA024566B1 (ru) | 2016-09-30 |
| EP2635264B8 (en) | 2018-07-18 |
| NL2007716A (en) | 2012-05-07 |
| KR20130101102A (ko) | 2013-09-12 |
| AR083769A1 (es) | 2013-03-20 |
| EP2635264A1 (en) | 2013-09-11 |
| BR112013010884A2 (pt) | 2016-08-02 |
| ES2405531B1 (es) | 2014-06-11 |
| JP5872573B2 (ja) | 2016-03-01 |
| NL2007716C2 (en) | 2012-11-13 |
| AU2011324995B2 (en) | 2015-12-24 |
| TW201223522A (en) | 2012-06-16 |
| ES2405531A2 (es) | 2013-05-31 |
| SG190018A1 (en) | 2013-06-28 |
| BE1019493A3 (fr) | 2012-07-03 |
| MX2013004972A (es) | 2013-08-27 |
| CN103384516A (zh) | 2013-11-06 |
| IL225892A0 (en) | 2013-06-27 |
| EA201300539A1 (ru) | 2013-09-30 |
| JP2014500246A (ja) | 2014-01-09 |
| NZ611148A (en) | 2015-09-25 |
| TWI520730B (zh) | 2016-02-11 |
| WO2012059724A1 (en) | 2012-05-10 |
| US20130225692A1 (en) | 2013-08-29 |
| MY164204A (en) | 2017-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY164204A (en) | Formulations comprising polyethylene glycol | |
| HN2011003011A (es) | Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas | |
| WO2011110939A3 (en) | Pharmaceutical compositions of substituted benzhydrylpiperazines | |
| WO2014186742A3 (en) | Anhydrous hydrogel composition | |
| MY161595A (en) | Oral care compositions | |
| WO2009063222A3 (en) | Solid compositions | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| PH12012501620A1 (en) | Oral care compositions | |
| MY157673A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| MX342323B (es) | Composicion solida para la administracion oral de tintes y uso de diagnostico de la misma. | |
| MX2019012939A (es) | Formulaciones que contienen linaclotida para administracion oral. | |
| WO2010021607A3 (en) | Pharmaceutical formulation | |
| EA201290116A1 (ru) | Новые композиции 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина | |
| WO2011002422A3 (en) | Solubility enhancing pharmaceutical formulation | |
| WO2012085284A3 (en) | High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts | |
| WO2011142731A3 (en) | Formulations comprising a third generation cephalosporin and clavulanic acid | |
| WO2012064302A3 (en) | Improved montelukast formulations | |
| EP4233915A3 (en) | Modified release formulations of viloxazine | |
| IN2014MN01382A (enExample) | ||
| WO2011139249A3 (en) | Pharmaceutical composition comprising cefdinir | |
| WO2011039675A3 (en) | Latrepirdine transdermal therapeutic dosage forms | |
| TR201803451T4 (tr) | Olmesartan formülasyonlari. | |
| TN2013000172A1 (en) | Formulations comprising polyethylene glycol | |
| WO2012093971A3 (en) | Effervescent compositions comprising amlodipine | |
| TR201203084A2 (tr) | Sefditoren pivoksil ve klavulanik asit içeren formülasyonlar. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |